The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias

Emmanuel Mignot, MD, PhD; Gert Jan Lammers, MD, PhD; Beth Ripley, MS; Michele Okun, MA; Sonia Nevsimalova, MD, PhD; Sebastiaan Overeem, MS; Jitka Vankova, MD; Jed Black, MD; John Harsh, PhD; Claudio Bassetti, MD; Harald Schrader, MD; Seiji Nishino, MD, PhD

Context: Narcolepsy, a neurological disorder affecting 1 in 2000 individuals, is associated with HLA-DQB1*0602 and low cerebrospinal fluid (CSF) hypocretin (orexin) levels.

Objectives: To delineate the spectrum of the hypocretin deficiency syndrome and to establish CSF hypocretin-1 measurements as a diagnostic tool for narcolepsy.

Design: Diagnosis, HLA-DQ, clinical data, the multiple sleep latency test (MSLT), and CSF hypocretin-1 were studied in a case series of patients with sleep disorders from 1999 to 2002. Signal detection analysis was used to determine the CSF hypocretin-1 levels best predictive for International Classification of Sleep Disorders (ICSD)–defined narcolepsy (blinded criterion standard). Clinical and demographic features were compared in narcoleptic subjects with and without low CSF hypocretin-1 levels.

Setting: Sleep disorder and neurology clinics in the United States and Europe, with biological testing performed at Stanford University, Stanford, Calif.

Participants: There were 274 patients with narcolepsy; hypersomnia; obstructive sleep apnea; restless legs syndrome; insomnia; and atypical hypersomnia cases such as familial cases, narcolepsy without cataplexy or without HLA-DQB1*0602, recurrent hypersomnias, and symptomatic cases (eg, Parkinson disease, depression, Prader-Willi syndrome, Niemann-Pick disease type C). The subject group also included 296 controls (healthy and with neurological disorders).

Intervention: Venopuncture for HLA typing, lumbar puncture for CSF analysis, primary diagnosis using the International Classification of Sleep Disorders, Stanford Sleep Inventory for evaluation of narcolepsy, and sleep recording studies.

Main Outcome Measures: Diagnostic threshold for CSF hypocretin-1, HLA-DQB1*0602 positivity, and clinical and polysomnographic features.

Results: HLA-DQB1*0602 frequency was increased in narcolepsy with typical cataplexy (93% vs 17% in controls), narcolepsy without cataplexy (56%), and in essential hypersomnia (52%). Hypocretin-1 levels below 110 pg/mL were diagnostic for narcolepsy. Values above 200 pg/mL were considered normal. Most subjects with low levels were HLA-DQB1*0602–positive narcolepsy-cataplexy patients. These patients did not always have abnormal MSLT. Rare subjects without cataplexy, DQB1*0602, and/or with secondary narcolepsy had low levels. Ten subjects with hypersomnia had intermediate levels, 7 with narcolepsy (often HLA negative, of secondary nature, and/or with atypical cataplexy or no cataplexy), and 1 with periodic hypersomnia. Healthy controls and subjects with other sleep disorders all had normal levels. Neurological subjects had generally normal levels (n=194). Intermediate (n=30) and low (n=3) levels were observed in various acute neuro-pathologic conditions.

Conclusions: Narcolepsy-cataplexy with hypocretin deficiency is a genuine disease entity. Measuring CSF hypocretin-1 is a definitive diagnostic test, provided that it is interpreted within the clinical context. It may be most useful in cases with cataplexy and when the MSLT is difficult to interpret (ie, in subjects already treated with psychoactive drugs or with other concurrent sleep disorders).

Arch Neurol. 2002;59:1553-1562

Narcolepsy is characterized by sleepiness and abnormal rapid eye movement (REM) sleep events such as cataplexy, hypnagogic hallucinations, and sleep paralysis.1-3 Prevalence is in 0.02% to 0.05% of the population,4,5 with onset generally occurring in adolescence.1-3 Quality of life is as impaired as in epilepsy or depression.6 Most cases are sporadic, but twin and family studies demonstrate the existence of genetic factors.1,3 Current treatment involves psychostimulants for sleepiness and...
antidepressants for cataplexy.\textsuperscript{22} \(\gamma\)-Hydroxybutyrate is used to consolidate nocturnal sleep and reduce cataplexy.\textsuperscript{2,7,8}

In the International Classification of Sleep Disorders (ICSD),\textsuperscript{9} narcolepsy is defined by sleepiness plus cataplexy, or by polysomnographic documentation of REM sleep abnormalities. The most commonly accepted diagnostic test is the multiple sleep latency test (MSLT).\textsuperscript{10} In which nocturnal polysomnography is performed, followed by 4 to 5 daytime naps during which sleep latency is measured.\textsuperscript{9,12} Untreated patients display short mean sleep latency (MSL) (≤5 or ≤8 minutes) and 2 or more sleep onset REM periods (SOREMPs).\textsuperscript{9,12} Using the polysomnographic definition, narcolepsy contrasts with idiopathic hypsomnia, which is a condition characterized by extended sleep time, no REM-related symptoms, and a short MSL without SOREMPs.\textsuperscript{9,13}

The nosology of narcolepsy is controversial. First, narcolepsy can be diagnosed by patient history alone.\textsuperscript{9} This may not always be accurate, as cataplexy overlaps with experiences reported by healthy subjects.\textsuperscript{9,14} Second, up to 15% of typical narcoleptic patients test negative on the MSLT.\textsuperscript{11,12} Third, controls and patients with other sleep disorders may have short MSL and multiple SOREMPs.\textsuperscript{11} Finally, sleep paralysis and hypnagogic hallucinations are common in the general population.\textsuperscript{15,16} The greatest difficulty is distinguishing narcolepsy without cataplexy from idiopathic hypsomnia. A definition based on the presence (narcolepsy without cataplexy) or absence (idiopathic hypsomnia) of 2 SOREMPs on the MSLT is usually adopted \textsuperscript{9,11} but some investigators suggest a continuum between these entities.\textsuperscript{17,18}

The observation that narcolepsy was associated with HLA-DR2 was the first suggestion of etiological homogeneity in narcolepsy.\textsuperscript{19} Recent studies have shown that HLA-DQB1*0602 is the main susceptibility allele.\textsuperscript{20,21} However, 12% to 38% of controls are DQB1*0602 positive.\textsuperscript{22} Clinical and HLA typing studies have identified cataplexy as the most specific symptom, with probable disease heterogeneity in patients without cataplexy.\textsuperscript{17,17} HLA-DQB1*0602 positivity is 90% to 100% in patients with definite cataplexy, but it decreases with atypical cataplexy or no cataplexy (40%).\textsuperscript{3,21} Even in cataplectic patients, substantial differences in HLA association exist (70%-100%), suggesting that cataplexy may be overdiagnosed.\textsuperscript{3,21}

The pathophysiology of narcolepsy involves abnormal hypocretin (orexin) neurotransmission. In a canine model, the disorder is caused by hypocretin receptor-2 mutations.\textsuperscript{23} Preprohypocretin (the precursor to 2 peptides: hypocretin-1 and hypocretin-2) knockout mice have narcolepsy.\textsuperscript{24} Human narcolepsy is generally not due to gene mutations, but hypocretin neurotransmission is impaired. The condition is associated with undetectable and, more rarely, elevated hypocretin-1 levels in the cerebrospinal fluid (CSF).\textsuperscript{25-28} A selective loss of hypocretin messenger RNA (mRNA) and immunoreactivity has also been reported in the hypothalamus of 6 patients.\textsuperscript{29,30} Together with the HLA association, these results suggest that most human cases are caused by an autoimmune-mediated destruction of hypocretin neurons.

The hypocretins were originally believed to be regulators of appetite.\textsuperscript{31,32} Despite their discrete location in the lateral and perifornical hypothalms, hypocretin neurons project widely throughout the brain, including dense excitatory projections to monoaminergic cell groups.\textsuperscript{33} Hypocretin neurons are therefore uniquely positioned to drive monoaminergic activity across the sleep cycle.\textsuperscript{34-37} Loss of this excitatory input may explain the abnormalities seen in narcolepsy.\textsuperscript{35,36} The hypocretins may also link energy metabolism and sleep.\textsuperscript{30-36}

In this study, we describe the spectrum of the hypocretin deficiency syndrome by analysis of CSF hypocretin-1 levels, and clinical, polysomnographic, and HLA data in more than 250 patients with various sleep disorders. This is the first study to offer definitive information on the use of CSF hypocretin-1 measurement for the diagnosis of narcolepsy.

### SUBJECTS AND METHODS

**SUBJECTS**

This was a prospective study. Table 1 presents categories and inclusion criteria. Patients and controls gave informed consent for the study, and lumbar puncture and venipuncture (for HLA typing) were performed. Patients with a sleep disorder (and their relatives, when applicable) were identified at Stanford University (Stanford, Calif; n=148), Leiden University Medical Center (Leiden, the Netherlands; n=66), Charles University (Prague, Czech Republic; n=23), Zürich University Hospital (Zürich, Switzerland; n=21), University of Southern Mississippi (Hattiesburg; n=13), and Trondheim University Hospital (Trondheim, Norway; n=2). Five patients were contributed by Dr Rye (Emory University School of Medicine, Atlanta, Ga). One case with central hypoventilation syndrome and possible narcolepsy was referred by Dr Halbower (John Hopkins University, Baltimore, Md).

Unrelated controls were healthy subjects without a known sleep disorder (n=64) recruited at Stanford University (n=43), Charles University (n=13), and Leiden University Medical Center (n=8). Patients with various neurological disorders undergoing a lumbar puncture (n=228) were also included. These included 16 new patients recruited at St Charles (n=12) and Emory (n=4), plus 212 previously described patients.\textsuperscript{27}

Sleep disorders were diagnosed clinically and using sleep studies. Patients were classified based on their primary ICSD diagnosis, blind of HLA and hypocretin-1 results. Seventeen controls had their lumbar puncture during nighttime. All others were studied during daytime (Table 1). This study includes 212 controls with various neurological disorders, 15 healthy controls, 22 hypsomnias patients, and 43 narcolepsy-cataplexy patients previously reported.\textsuperscript{25-27,40} Patient ethnicity was 88% white (Europeans and North Americans), 7% Asian (Chinese, Japanese, and Korean Americans), 2% Black (African Americans), and 3% Latino and mixed.

In narcolepsy, the existence of “definite” cataplexy vs “atypical or doubtful” cataplexy was confirmed using interviews and a validated inventory.\textsuperscript{14} Most subjects were treated with amphetamine-like stimulants, modafinil, antidepressants, and \(\gamma\)-hydroxybutyrate (Table 1). An effort was made to include patients with unusual forms of narcolepsy. 27 subjects from 9 multiplex families (4 with HLA-negative cases), and 7 HLA-DQB1*0602–negative patients with cataplexy.

Idiopathic hypsomnia was diagnosed by ICSD criteria.\textsuperscript{9} Most patients (83%) had typical (MSL <10 minutes, 0-1 SOREMP) MSLT (MSL ± SE=7.1±0.7 minutes; mean ± SE SOREMPs = 0.07±0.05). Patients with periodic hypsomnia (n=3) all had more than 6 previous episodes (by ICSD criteria\textsuperscript{9}; 2 untreated, 1 treated with modafinil). Those with obstructive sleep apnea (OSA) had a respiratory disturbance index of 10 epi-
TABLE 1. Definition of Diagnostic Categories and Demographic Data of the Sample Under Study

<table>
<thead>
<tr>
<th>Groups</th>
<th>No. of Subjects</th>
<th>Diagnostic Criteria/Comments</th>
<th>Sex, % Male</th>
<th>Mean ± SEM Age, y</th>
<th>Treated Subjects, %†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daytime</td>
<td>47</td>
<td>Healthy control subjects, LP during daytime (9 AM-7 PM)</td>
<td>53</td>
<td>48.5 ± 2.7</td>
<td></td>
</tr>
<tr>
<td>Nighttime</td>
<td>17</td>
<td>Healthy control subjects, LP during nighttime (11 PM-6 AM)</td>
<td>65</td>
<td>38.6 ± 4.5</td>
<td></td>
</tr>
<tr>
<td>Neurological disorder</td>
<td>228</td>
<td>Patients with various neurological diseases, without sleep disturbances</td>
<td>54</td>
<td>39.0 ± 1.7</td>
<td></td>
</tr>
<tr>
<td>Narcolepsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narcolepsy with typical cataplexy</td>
<td>101</td>
<td>History of cataplexy triggered by joking or laughing</td>
<td>52</td>
<td>39.2 ± 1.6</td>
<td></td>
</tr>
<tr>
<td>Narcolepsy with atypical cataplexy</td>
<td>29</td>
<td>History of cataplexy triggered by events other than joking or laughing</td>
<td>45</td>
<td>38.7 ± 2.5</td>
<td></td>
</tr>
<tr>
<td>HLA-negative narcolepsy/cataplexy</td>
<td>7</td>
<td>History of typical cataplexy, HLA-DQB1*0602 negative</td>
<td>57</td>
<td>31.4 ± 5.0</td>
<td></td>
</tr>
<tr>
<td>Narcolepsy without cataplexy</td>
<td>20</td>
<td>No cataplexy, MSL &gt;8 minutes plus 2 or more SOREMPs</td>
<td>60</td>
<td>33.3 ± 2.6</td>
<td></td>
</tr>
<tr>
<td>Members of families with narcolepsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Narcolepsy (proband)</td>
<td>9</td>
<td>4 Probands from HLA-DQB1*0602−negative families</td>
<td>44</td>
<td>54.3 ± 6.0</td>
<td></td>
</tr>
<tr>
<td>Narcolepsy (nonproband)</td>
<td>11</td>
<td></td>
<td>36</td>
<td>40.6 ± 4.7</td>
<td></td>
</tr>
<tr>
<td>Idiopathic/undocumented hypnosomia</td>
<td>3</td>
<td></td>
<td>33</td>
<td>38.3 ± 1.9</td>
<td></td>
</tr>
<tr>
<td>Healthy relatives</td>
<td>4</td>
<td></td>
<td>50</td>
<td>41.3 ± 11.6</td>
<td></td>
</tr>
<tr>
<td>Other hypsomas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Idiopathic hypnosomia</td>
<td>12</td>
<td>According to ICSD criteria</td>
<td>13</td>
<td>41.4 ± 6.9</td>
<td></td>
</tr>
<tr>
<td>Periodic hypnosomia</td>
<td>3</td>
<td>According to ICSD criteria (one subject during an episode)</td>
<td>38</td>
<td>38.2 ± 2.2</td>
<td></td>
</tr>
<tr>
<td>Secondary hypnosomia/cataplexy</td>
<td>28</td>
<td>Various disorders‡</td>
<td>100</td>
<td>27.3 ± 9.4</td>
<td></td>
</tr>
<tr>
<td>Undocumented hypnosomia</td>
<td>7</td>
<td>Complaint of hypnosomia, without confirmatory sleep testing</td>
<td>50</td>
<td>40.2 ± 4.5</td>
<td></td>
</tr>
<tr>
<td>Other sleep disorders</td>
<td></td>
<td></td>
<td>43</td>
<td>36.3 ± 5.1</td>
<td></td>
</tr>
<tr>
<td>Obstructive sleep apnea</td>
<td>15</td>
<td>Snoring patients, respiratory disturbance index &gt;10/hour</td>
<td>80</td>
<td>40.0 ± 3.2</td>
<td></td>
</tr>
<tr>
<td>Restless legs syndrome</td>
<td>10</td>
<td>According to ICSD criteria</td>
<td>30</td>
<td>52.2 ± 4.9</td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>12</td>
<td>According to ICSD criteria</td>
<td>42</td>
<td>45.9 ± 4.2</td>
<td></td>
</tr>
</tbody>
</table>

*LP indicates lumbar puncture; MSL, multiple sleep latency; SOREMPs, sleep onset rapid eye movement periods; ICSD, International Classification of Sleep Disorders; and ellipses, not applicable.
†Treatment performed using an established pharmacological and/or nonpharmacological treatment for the condition.
‡See Table 3.

CLINICAL SAMPLE AND HLA TYPING
Age, sex, and ethnicity did not differ across groups (Table 1). Higher body mass index (BMI; calculated as weight in kilograms divided by the square of height in meters) was observed in patients with OSA, narcolepsy-cataplexy, atypical or doubtful cataplexy, and idiopathic hypersomnia (Table 2). When compared with controls (18% of 64 subjects), the highest DQB1*0602 values were observed in patients with narcolepsy-cataplexy (93%; odds ratio [OR]=80; P<.001), followed by those with narcolepsy without cataplexy (56%; OR=7.0; P<.01), patients with idiopathic hypersomnia (52%; OR=6.0; P<.01), narcolepsy family members (P<.01), and patients with atypical cataplexy (35%; OR=3.3; P=.05).

CSF HYPOCRETIN-1 IN CONTROL SUBJECTS AT VARIOUS CIRCADIAN TIMES
Age, sex, ethnicity, HLA-DQB1*0602, BMI, and time of day did not affect hypocretin-1 levels in healthy controls (Table 2). This confirms data from healthy volunteers using intrathecal catheters in whom lumbar CSF levels were only slightly (15%) higher at night (E.M. and Ron Salomon, MD, unpublished data, 2002).

DEFINING HYPOCRETIN DEFICIENCY
Directly measured and extracted hypocretin-1 levels were highly correlated throughout the entire sample (r=.86, P<.001). Levels were lower in patients with narcolepsy with
low levels were patients with ICSD-defined narcolepsy. Using the 110-pg/mL threshold, 106 of 113 patients with narcolepsy subjects.

Typical cataplexy, in subjects with atypical cataplexy, and in patients with neurological disorders (Figure 1); 3 had acute Guillain-Barré syndrome, and their cases have been reported27; one was a 38-year-old man with a subacute history of change in behavior who became comatose. He was later diagnosed with Hashimoto thyroiditis.

**GROUPS WITH NORMAL HYPOCRETIN-1 LEVELS**

Several groups had mostly normal levels (Figure 1). These included patients with idiopathic hypersomnia (all but one with intermediate levels), OSA, restless leg syndrome, and insomnia. Interestingly, 2 patients with OSA and normal levels had residual sleepiness despite successful continuous pressure airway pressure therapy therapy (1 HLA-negative patient, MSLT SL = 3.9, 1 SOREMP; 1 HLA-positive patient, MSLT SL = 8.0, no SOREMP).

**GROUPS WITH INTERMEDIATE HYPOCRETIN-1 LEVELS**

Only 10 subjects in our sleep disorder series had intermediate levels (Figures 1 and 2). Three also had intermediate levels using the extracted assay (≤ 150 pg/mL) and are most likely to have partial hypocretin deficiency. The first pa-
tient was HLA positive with periodic hypersomnia in the midst of an episode. The second had idiopathic hypersomnia and was the son of a patient with narcolepsy-cataplexy (Figure 2, “VER” family); this subject had sleepiness, hypnagogic hallucinations, and sleep paralysis, but a negative MSLT (MSL=9 minutes, 0 SOREM). The third is HLA positive with a 9-year history of narcolepsy-cataplexy, sleep paralysis, and hypnagogic hallucinations (MSLT was atypical, with an MSL of 3.4 minutes, but no SOREM). The other 7 subjects included 5 subjects with narcolepsy-cataplexy (3 HLA negative, 2 with atypical cataplexy), 1 with idiopathic hypersomnia, and 1 with hypersomnia undocumented by polysomnography.

Thirty of 228 subjects in our neurological disorder survey had intermediate levels. These previously described patients included subjects with head trauma, encephalitis, and Guillain-Barré syndrome. None of the 74 healthy controls had intermediate levels.

LOW HYPOCRETIN-1 LEVELS IN NARCOLEPSY

Table 4 compares clinical data in narcoleptic patients with (n=106) and without (n=65) low CSF hypocretin-1 levels. Note that these subjects do not represent a random sample of narcoleptic patients, and include a higher number of subjects without cataplexy and/or HLA-DQB1*0602. We found that subjects with low hypocretin-1 levels had more typical cataplexy, more abnormal MSLTs, and were more frequently HLA positive. Other characteristics were generally similar. Typical cataplexy was a better predictor of a low hypocretin-1 level than abnormal MSLT. Of the 90 subjects with low hypocretin-1 levels and available MSLT, 77 (86%) had abnormal MSLT, but 11 (12%) had borderline MSLT (SL/H11021 8 minutes, 0-1 SOREMPS vs SL/H11022 8 minutes, 1 SOREM), and 2 (2%) had normal MSLT (SL/H11022 10 minutes, no SOREMPS). This contrasts with the highly predictive value of cataplexy. Of the 106 narcoleptic subjects with low levels, 97 (92%) had typical cataplexy, 6 (6%) had atypical/doubtful cataplexy, and only 3 (3%) had no cataplexy. We explored the value of low hypocretin levels in narcoleptic patents solely selected on the basis of typical cataplexy (Table 1). The sensitivity and specificity of low hypocretin-1 levels in 101 randomly selected patients with typical cataplexy vs 292 controls was extremely high (87% and 99%, respectively [PVP=96%, PVN=96%]). Of note, in 3 subjects with cataplexy and low CSF levels, disease duration was 6 months, 8 months, and 9 months, respectively, but levels were below the detection limit in both assays.

Figure 1. Cerebrospinal fluid hypocretin-1 levels (direct assay) across various disease categories. Each dot represents a single patient. Diagnostic categories are as detailed in Table 1. Hypocretin-1 values of 110 pg/mL or less were determined as the best cutoff point to diagnose International Classification of Sleep Disorders–defined narcolepsy. A second cutoff point of 200 pg/mL best determines healthy control values. The number of subjects with hypocretin values below or equal to 110 pg/mL, above 200 pg/mL, and between these 2 values is indicated for each category.
NARCOLEPSY WITHOUT CATAPLEXY AND LOW HYPOCRETIN-1 LEVELS

All 3 subjects without cataplexy who had low hypocretin-1 levels were HLA positive. Two patients with low but detectable hypocretin-1 levels (eg, >40 pg/mL and ≤110 pg/mL in the extracted assay) were young narcoleptic subjects (16 and 25 years old, respectively). One case, that of a 16-year-old girl (direct assay = 63 pg/mL; extracted assay = 98 pg/mL), was somewhat atypical; she had narcolepsy without cataplexy following an undetermined viral illness and generalized lymphadenopathy. Remarkably, in the case of a 58-year-old patient with a 45-year history of narcolepsy, there were mild hypnagogic hallucinations and no sleep paralysis. This thoroughly interviewed patient had undetectable levels using both assays in 2 independent lumbar punctures.

HLA-NEGATIVE NARCOLEPSY WITH LOW HYPOCRETIN-1 LEVELS

Only 3 narcolepsy subjects with low levels were HLA-DQB1*0602 negative. One subject had a previously reported preprohypocretin gene mutation (including because of HLA negativity and unusually early onset at 6 months). The second subject had mild cataplexy, no ancillary symptoms, and a positive MSLT (undetectable levels using both assays in 2 independent lumbar punctures). Onset was unremarkable at 11 years of age, but hypocretin mutation screening was negative (data not shown). The third had mild/atypical cataplexy, no ancillary symptoms, and MSLT indicating borderline sleepiness (MSL = 10.6 minutes, 1 SOREMP).

FAMILIAL CASES

Nine multiplex families were studied (Figure 2). The results correlated with HLA typing. In 2 families with cataplexy and abnormal MSLT cases (the “EIC” and “RIC” families, respectively), hypocretin-1 levels were normal. One family (“TER”) included an HLA-negative subject with normal levels, typical cataplexy, multiple SOREMPs, but no subjective sleepiness. Of special interest was the study of the “DAN” family, a large African American lineage with 7 affected subjects, 6 of whom reported typical cataplexy. The 3 eldest subjects with narcolepsy-cataplexy were hypocretin-deficient, while the other 4, generally younger, had normal CSF hypocretin-1 levels (Figure 2).

NORMAL HYPOCRETIN-1 LEVELS IN NARCOLEPSY

Data from these subjects (n=65) are reported in Table 4. These subjects were younger and without (26%) or with (35%) atypical or doubtful cataplexy. Most were HLA negative (66%), and many had a family history of illness (26%). Importantly, these patients did not have recent disease onset, making it unlikely that they will develop cataplexy. Delays between onset and hypocretin-1 measurements were similar in subjects with low and normal levels.
HYPOCRETIN-1 IN SECONDARY HYPERSONMIA/CATAPLEXY

Eighteen subjects were studied (Table 3, Figure 1). Three had low hypocretin-1 levels — a child with central hypoventilation syndrome and narcolepsy-like symptoms, a patient with a probable hypothalamic pathological illness, and a patient with Prader-Willi syndrome. Notably, a subject with Niemann-Pick disease type C and severe cataplexy had normal levels.

COMMENT

In this large study, low CSF hypocretin-1 levels were consistently observed in those with narcolepsy-cataplexy. Two approaches were used — a direct radioimmunoassay and measurements after extraction. Both techniques were reliable and highly correlated. A cut-off of 110 pg/mL (representing 30% of the normal mean value in the direct assay) was determined to have the best sensitivity/specificity ratio. Since the direct assay is more cost effective and less labor intensive, we propose using this test for diagnostic purposes. All subjects with a sleep disorder who tested positive by this criteria had narcolepsy (Figure 1). Importantiy, a subset of patients without positive MSLT, without the classic HLA marker, and/or without cataplexy also tested positive.

We found that 3 subjects with secondary hypersomnia (Table 3) had levels below 110 pg/mL, indicating the existence of genuine cases of secondary hypocretin deficiency. This extends on 3 previously reported cases with secondary narcolepsy-cataplexy—one with autosomal dominant cerebellar ataxia, deafness, and the other 2 with large vascular and tumoral hypothalamic lesions.44-46 Of note, the new cases reported in this study may also have included impaired hypothalamic function. Prader-Willi syndrome, a syndrome characterized by obesity, hypotonia, and daytime sleepiness (not always explained by OSA), has long been suspected to involve hypothalamic abnormalities.47-48 Similarly, late-onset central hypoventilation syndrome is often associated with hypothalamic dysfunction.50 These cases illustrate the value of the CSF test in patients otherwise difficult to diagnose.

This series was also used to describe the clinical spectrum of the narcolepsy with hypocretin deficiency syn-
Table 4. Demographic and Clinical Data of ICSD Narcoleptic Subjects With Low and Normal Hypocretin-1 Levels*

<table>
<thead>
<tr>
<th>Variable</th>
<th>Low Hypocretin-1 Level</th>
<th>Normal Hypocretin-1 Level</th>
<th>P Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total No. of subjects</td>
<td>106</td>
<td>65</td>
<td>...</td>
</tr>
<tr>
<td>Male sex (%)</td>
<td>51</td>
<td>48</td>
<td>...</td>
</tr>
<tr>
<td>Mean ± SEM age, y</td>
<td>40.7 ± 1.7</td>
<td>36.4 ± 1.5</td>
<td>...</td>
</tr>
<tr>
<td>Age of onset (range), y</td>
<td>18 (0.5-53)</td>
<td>15 (2-40)</td>
<td>&lt;.05</td>
</tr>
<tr>
<td>Mean ± SEM delay between onset and CSF tap, y</td>
<td>19.3 ± 1.6</td>
<td>19.9 ± 1.9</td>
<td>...</td>
</tr>
<tr>
<td>Race (% white)</td>
<td>87</td>
<td>86 (65)</td>
<td>...</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>27.9 ± 1.7</td>
<td>26.2 ± 0.7</td>
<td>...</td>
</tr>
<tr>
<td>HLA-DQB1*0602 (% positive)</td>
<td>97</td>
<td>34</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Family history (%)</td>
<td>10</td>
<td>26</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Treated (%)</td>
<td>73</td>
<td>66</td>
<td>...</td>
</tr>
<tr>
<td>Cataplexy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Absent</td>
<td>3</td>
<td>26</td>
<td>&lt;.05</td>
</tr>
<tr>
<td>% Atypical</td>
<td>6</td>
<td>35</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>% Typical</td>
<td>92</td>
<td>38</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Sleepiness and MSLT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleepiness, % of patients on self-report</td>
<td>100</td>
<td>96</td>
<td>...</td>
</tr>
<tr>
<td>Mean ± SEM Epworth sleepiness scale, score</td>
<td>17.5 ± 0.4</td>
<td>17.4 ± 0.5</td>
<td>...</td>
</tr>
<tr>
<td>MSLT, No. of MSLS (range)</td>
<td>2.7 (0-15)</td>
<td>4.8 (0-15)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>MSLT, No. of SOREMPs (range)</td>
<td>3 (0-5)</td>
<td>2 (0-4)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>SLE ≤5 =2 SOREMP, % of patients</td>
<td>78</td>
<td>48</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>SLE ≤8 =2 SOREMP, % of patients</td>
<td>86</td>
<td>59</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Other symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep paralysis, % of patients</td>
<td>63</td>
<td>71</td>
<td>...</td>
</tr>
<tr>
<td>Hypnagogic hallucinations, % of patients</td>
<td>85</td>
<td>78</td>
<td>...</td>
</tr>
<tr>
<td>Obstructive sleep apnea, % of patients‡</td>
<td>23</td>
<td>30</td>
<td>...</td>
</tr>
<tr>
<td>Periodic limb movement during sleep, % of patients‡</td>
<td>26</td>
<td>19</td>
<td>...</td>
</tr>
</tbody>
</table>

*Variables were occasionally calculated with a slightly smaller number of subjects (>80%) than the total indicated in each category. ICSD indicates International Classification of Sleep Disorders; CSF, cerebrospinal fluid; MSL(T), multiple sleep latency (test); and SOREMP, sleep-onset rapid eye movement period. Subjects with secondary hypersonnia or narcolepsy are not included (non-ICSD-defined narcolepsy). Narcoleptic subjects with normal hypocretin levels are over represented as subjects were included independent of recruitment procedures (eg, inclusion of familial or noncataplectic subjects).

†Values determined after Bonferroni correction.

‡Data were available for a subset of patients representing 50% of the groups.

For Table 4, the measure of hypocretin-1 levels was found to be significantly influenced by the use of psychotropic medications (antidepressants, dopamine agonists, hypnotics, stimulant compounds) or by the presence of other sleep disorders. Hypocretin-1 testing may therefore be most useful in cataplectic patients in whom treatment has been initiated, and/or when other sleep disorders may confound the MSLT (eg, insufficient sleep, OSA).

The MSLT remains the test of choice in patients without cataplexy since very few subjects (n = 3) in this category had low CSF hypocretin-1 levels. A similar result was recently reported in another study.28 Another limitation of the CSF test is the occurrence of post–lumbar puncture headaches in 5% to 10% of the cases. Lumbar punctures are, however, more generally available and may be cheaper than the 2-day MSLT. The MSLT and CSF tests are also difficult to compare, as the MSLT measures a physiological process (daytime sleepiness), while the CSF test measures a neurochemical abnormality. These 2 tests should, therefore, be considered complementary in most cases.

The finding that cases with secondary hypersonnia, periodic hypersonnia and/or atypical narcolepsy have intermediate or low levels is noteworthy. Periodic hypersonnia, often associated with increased appetite and hypersexuality, has been suspected to involve hypothalamic abnormalities,5253 and our finding supports this hypothesis. In our survey, 30 of 228 patients with various neurological conditions had intermediate levels. These subjects include patients with head trauma, encephalitis, and Guillain-Barré syndrome, which may alter hyp-
pothalamic function, and more rarely, narcolepsy-cataplexy (eg, in the context of the encephalitis lethargica epidemic). 56-60 Intermediate levels may thus point toward a secondary hypothalamic dysfunction. Alternatively, these levels may reflect changes in CSF flow or blood-brain barrier permeability and should be interpreted in the clinical context.

The majority of patients with idiopathic hypersomnia and narcolepsy without cataplexy had normal hypocretin-1 levels. A parsimonious explanation may be that the etiology of these cases does not involve hypocretins, and that narcolepsy with typical cataplexy is a distinct entity. It also indicates that differentiating narcolepsy without cataplexy and idiopathic hypersomnia may not be justified etiologically, as others have suggested. 17,18 Surprisingly, however, HLA-DQB1*0602 frequency was increased in noncataplexy cases (Table 2), paralleling previous reports. 17,21 A small number of patients with typical cataplexy also had normal levels, especially multiplex and HLA-negative subjects (Figure 1 and 2). Hypersomnia and narcolepsy-cataplexy may thus be part of the same disease continuum. In this model, some narcolepsy patients have hypocretin deficiency in projection areas important for sleep regulation, but they still have normal CSF levels, especially younger subjects without HLA-DQB1*0602. Partial hypocretin deficiency would be associated with less severe symptomatology and less frequent cataplexy.

Accepted for publication April 29, 2002.

From the Center for Narcolepsy, Stanford University, Stanford, Calif (Drs Mignot, Black, Nishino, and Ms Ripley and Okun); the Department of Neurology and Clinical Neurophysiology, Leiden University Medical Center, Leiden, the Netherlands (Dr Lammers and Mr Overeem); the Department of Neurology, Charles University, Prague, Czech Republic (Drs Nevsimalova and Vankova); University of Southern Mississippi, Hattiesburg (Dr Harsh); the Department of Neurology, Zurich University Hospital, Zurich, Switzerland (Dr Bassetti); and the Department of Neurology, Trondheim University Hospital, Trondheim, Norway (Dr Schrader).

Author contributions: Study concept and design (Drs Mignot, Lammers, Nevsimalova, Bassetti, and Schrader); acquisition of data (Drs Mignot, Lammers, Nevsimalova, Vancova, Black, Harsh, Bassetti, and Nishino, Ms Ripley and Okun, and Mr Overeem); analysis and interpretation of data (Drs Mignot and Lammers, and Mr Overeem); drafting of the manuscript (Drs Mignot, Lammers, and Harsh and Ms Ripley); critical revision of the manuscript for important intellectual content (Drs Mignot, Lammers, Nevsimalova, Vancova, Black, Bassetti, Schrader, and Nishino and Mr Overeem); statistical expertise (Dr Mignot); obtained funding (Drs Mignot, Nevsimalova, Black, and Bassetti); administrative, technical, and material support (Drs Mignot, Lammers, Nevsimalova, Vancova, Harsh, Bassetti, Schrader, and Nishino, Ms Okun, and Mr Overeem); study supervision (Dr Mignot).

This study was supported by grants NS 23724, NS 33797, and MH40041 from the National Institutes of Health (Bethesda, Md); and grants GA UK 56/99 and MSM 11110001 from the Czech Republic. Mr Overeem was supported by the foundation De Drie Lichten (Rotterdam, the Netherlands) and Hersentichting Nederland (Den Haag, the Netherlands).

We thank David Rye, MD, for providing cerebrospinal fluid samples; Paul Stowers, MS, and David Brooks for assistance in organizing and performing lumbar punctures; Ling Lin, MD, PhD, for HLA typing; Anna Voros for technical assistance; Geoffrey Harwig for collection of the clinical data in a large African American lineage; Shahrad Taheri, MD, PhD, and Andrew Ray, PhD, for editing the manuscript; Jamie Zeitzer, PhD, for editing and preparation of the figures; and Helena Kraemer, PhD, for statistical assistance with the quality receiver operating characteristic analysis.

Corresponding author and reprints: Emmanuel Mignot, MD, Center for Narcolepsy, Stanford University, 701B Lower Welch Rd, Palo Alto, CA 94304-5742 (e-mail: mignot@leland.stanford.edu).

REFERENCES

22. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer...


